Entera Bio/$ENTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Entera Bio
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
- Ticker
- $ENTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 21
- Headquarters
- Jerusalem, Israel
- Website
- enterabio.com
Entera Bio Metrics
BasicAdvanced
$512M
-
-$0.35
1.40
-
Price and volume
Market cap
$512M
Beta
1.4
52-week high
$4.20
52-week low
$0.91
Average daily volume
384K
Financial strength
Current ratio
8.981
Quick ratio
5.425
Long term debt to equity
0.031
Total debt to equity
0.058
Interest coverage (TTM)
-5.30%
Profitability
EBITDA (TTM)
-14.369
Management effectiveness
Return on assets (TTM)
-45.98%
Return on equity (TTM)
-138.92%
Valuation
Price to book
20.08
Price to tangible book (TTM)
20.08
Price to free cash flow (TTM)
-13.006
Free cash flow yield (TTM)
-7.69%
Free cash flow per share (TTM)
-0.228
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
39.31%
3-year earnings per share growth (CAGR)
-1.37%
Bulls say / Bears say
In June 2026, the FDA accepted Entera’s streamlined Phase 3 protocol for EB613, setting total hip BMD change at Month 12 as the primary endpoint, which clarifies the regulatory path to NDA submission (GlobeNewswire)/(Entera Q2 2026 Results).
Entera secured $275 million in an oversubscribed July 2026 private placement led by BVF Partners and top-tier institutional investors, funding the EB613 Phase 3 program through NDA submission and extending cash runway into 2030 (Investing.com)/(Entera Q2 2026 Results).
Late-breaking Phase 1 bridging data presented at ENDO 2026 showed that single-tablet EB613 achieved pharmacokinetic and pharmacodynamic profiles comparable to both the multi-tablet formulation and Forteo, de-risking the pivotal Phase 3 candidate selection (Entera Q2 2026 Results)/(Investing.com).
The July 2026 private placement issued 134.8 million ordinary shares and pre-funded warrants at $2.04 per share, representing significant dilution of existing equity and potential downward pressure on the stock price (Investing.com)/(SEC 8-K).
Phase 3 initiation is not planned until late 2026 with topline data only expected in the second half of 2028, delaying potential revenue and extending exposure to clinical execution and regulatory risk before an NDA can be filed (GlobeNewswire)/(Entera Q2 2026 Results).
Net loss widened to $7.3 million in Q2 2026 from $2.7 million a year ago, driven by increased R&D for Phase 3 preparations and OPKO collaborations, indicating high cash burn and potential need for additional funding even with recent financing (Investing.com)/(GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Upcoming events
No upcoming events
Entera Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.